Clinical Trial Update: Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the pharmacokinetics and safety of saroglitazar in adults with moderate hepatic impairment due to cholestatic liver disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholestatic Liver Disease

Drugs mentioned

• Saroglitazar (saroglitazar)

Snippet

Sponsor: Zydus Therapeutics Inc. | Conditions: Cholestatic Liver Disease | Phase 1 | Status: RECRUITING